Features of the treatment of osteoarthritis in patients with coronary heart disease


  • M.О. Romanov
  • V.О. Romanova
Keywords: osteoarthritis, gonarthrosis, coronary heart disease, «Theraflex®».

Abstract

The article presents the results of the study on the effect of a three-month application of «Theraflex®» in the complex therapy of comorbid pathology - osteoarthritis of the knee joints in combination with coronary heart disease. The positive drug effect on the symptoms of the combined pathology, both gonarthrosis and coronary heart disease, is shown. A conclusion is made about the active influence of «Theraflex®» on the pathogenetic mechanisms of gonarthrosis progression.

References

1. Kovalenko, V. M., & Bortkevych, O. P. (2010). Osteoartroz: praktychna nastanova. Kyiv: Morion. [in Ukrainian].

2. Ministerstvo okhorony zdorovia Ukrainy (2016). Stabilna ishemichna khvoroba sertsia: adaptovana klinichna nastanova, zasnovana na dokazakh. Kyiv. [in Ukrainian].

3. Nasonova, V. A. (2009). Osteoartroz – problema polimorbidnosti. Consilium Medicum, 1, 5-8. [in Russian].

4. 2013 ESC guidelines on the management of stable coronary artery disease. (2013). European Heart Journal, 34(38), 2949-3003. doi:10.1093/eurheartj/eht296.

5. Bruyère, O., Cooper, C., Pelletier, J., Maheu, E., Rannou, F., Branco, J., … Reginster, J. (2016). A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis – From evidence-based medicine to the real-life setting. Seminars in Arthritis and Rheumatism, 45(4). doi:10.1016/j.semarthrit.2015.11.010.

6. Fernandes, L., Hagen, K. B., Bijlsma, J. W., Andreassen, O., Christensen, P., Conaghan, P. G., … Vlieland, T. P. (2013). EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Annals of the Rheumatic Diseases, 72(7), 1125-1135. doi:10.1136/annrheumdis-2012-202745.

7. Fransen, M., Agaliotis, M., Nairn, L., Votrubec, M., Bridgett, L., Su, S., … Day, R. (2015). Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Annals of the Rheumatic Diseases, 74(5), 851-858. doi:10.1136/annrheumdis-2013-203954.

8. Gabriel, S. E., & Michaud, K. (2009). Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Research & Therapy, 11(3), 229. doi:10.1186/ar2669.

9. Haseeb, A., & Haqqi, T. M. (2013). Immunopathogenesis of osteoarthritis. Clinical Immunology, 146(3), 185-196. doi:10.1016/j.clim.2012.12.011.

10. Hochberg, M. C. (2008). Mortality in osteoarthritis. Clinical and Experimental Rheumatology, 26(51), 120-124.

11. Hochberg, M. C., Altman, R. D., April, K. T., Benkhalti, M., Guyatt, G., Mcgowan, J., … Tugwell, P. (2012). American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care & Research, 64(4), 465-474. doi:10.1002/acr.21596.

12. Hochberg, M. C., Martel-Pelletier, J., Monfort, J., Möller, I., Castillo, J. R., Arden, N., … Pelletier, J. (2016). Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Annals of the Rheumatic Diseases, 75(1), 37-44. doi:10.1136/annrheumdis-2014-206792.

13. Kadam, U. T., & Croft, P. R. (2007). Clinical comorbidity in osteoarthritis: associations with physical function in older patients in family practice. The Journal of Rheumatology, 34(9), 1899-1904.

14. Mcalindon, T., Bannuru, R., Sullivan, M., Arden, N., Berenbaum, F., Bierma-Zeinstra, S., … Underwood, M. (2014). OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and Cartilage, 22(3), 363-388. doi:10.1016/j.joca.2014.01.003.

15. Sherer, Y., & Shoenfeld, Y. (2006). Mechanisms of Disease: atherosclerosis in autoimmune diseases. Nature Clinical Practice Rheumatology, 2(2), 99-106. doi:10.1038/ncprheum0092.

16. Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M., … Juni, P. (2011). Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Bmj, 342(11), 70-86. doi:10.1136/bmj.c7086.

17. Whelton, A., & Gibofsky, A. (2011). Minimizing Cardiovascular Complications During the Treatment of Osteoarthritis. American Journal of Therapeutics, 18(6), 466-476. doi:10.1097/mjt.0b013e3181e1e218.
Published
2017-10-27
How to Cite
Romanov, M., & Romanova, V. (2017). Features of the treatment of osteoarthritis in patients with coronary heart disease. Biomedical and Biosocial Anthropology, (29), 133-136. Retrieved from https://bba-journal.com/index.php/journal/article/view/305